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ABSTRACT: Many preclinical studies seek cures for spinal cord injury
(SCI), but when the results are translated to clinical trials they give scant
eﬃcacy. One possible reason is that most strategies use treatments
directed toward a single pathological mechanism, while a multitherapeutic
approach needs to be tested to signiﬁcantly improve outcomes after SCI.
Most of the preclinical reports gave better outcomes when a combination
of diﬀerent compounds was used instead of a single drug. This promising
approach, however, must still be improved because it raises some criticism:
(i) the blood−spinal cord barrier limits drug distribution, (ii) it is hard to
understand the interactions among the pharmacological components after
systemic administration, and (iii) the timing of treatments is crucial: the
spread of the lesion is a process ﬁnely regulated over time, so therapies
must be scheduled at precise times during the postinjury course.
Nanomedicine could be useful to overcome these limitations. Nanotools
allow ﬁnely regulated drug administration in terms of cell selectivity and release kinetics. We believe that excellent therapeutic
results could be obtained by exploiting this tool in multitherapy. Combining nanoparticles loaded with diﬀerent compounds
that act on the main pathological pathways could overcome the restrictions of traditional drug delivery routes, a major limit for
the clinical application of multitherapy. This review digs into these topics, discussing the critical aspects of multitherapies now
proposed and suggesting new points of view.
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■ INTRODUCTION
Spinal cord injury (SCI) is a debilitating condition caused by
damage to the spinal cord. It is the most frequent disabling
spinal injury: an estimated 2.5 million people worldwide live
with SCI, and more than 130 000 new injuries are reported
every year1 (http://www.wingsforlife.com).
Persisting SCI has a physical, emotional, and economic
impact on patients and places a heavy burden on society in
terms of healthcare costs, primary care, and loss of income.2,3
Spinal cord trauma is the result of two phases. First, a primary
injury to the spinal cord occurs, causing tissue compression,
transection, contusion, or laceration. The most frequent causes
of primary mechanical trauma are auto or motorcycle or
bicycle accidents, falls, gunshot wounds, falling objects,
medical and surgical complications, person-to-person contact,
and pedestrian injuries. SCI can also result from no traumatic
causes such as infection, insuﬃcient blood ﬂow, and tumors.
This review will focus on traumatic SCI. From primary injury
arises a multifactorial secondary injury, involving a complex
pathological mechanism that starts after primary SCI and can
last months.4 These events include, but are not limited to,
neuronal injury and death, neuroinﬂammation, breakdown of
the blood−spinal cord barrier (BScB), and oxidative stress.
This results in autonomic, somatosensory, and/or motor
dysfunction below the lesion, with the progression of chronic
pain syndromes.
Up until now, the usual procedure in the case of SCI is
surgical stabilization and decompression of the spinal cord,
combined with high-dose methylprednisolone.5 This approach
is still controversial since it gives only limited improvements in
outcome, often with severe side eﬀects,6 so eﬀective therapy for
SCI remains a great challenge.
Our understanding of the pathophysiology of SCI has
greatly increased in recent decades as a result of fruitful
preclinical research. In particular, there have been remarkable
advances in our understanding of the secondary injury events,
and several diﬀerent secondary injury processes have been
identiﬁed.7,8 It is now clear that the main source of the
complexity of secondary injury is the diﬀerent starting time of
the various pathological processes involved. Inﬂammation
characterizes the acute phase after SCI (seconds to minutes),
when microglia begin to remove debris from the injured area.9
This leads to astrocyte activation, marking the subacute phase
(minutes to weeks), with the stabilization of a glial barrier to
the axonal regeneration.10 Finally, weeks, months, or even
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years after the injury (chronic phase), oligodendrocytes
continue to undergo apoptosis, leading to axon demyelination
and neuropathic pain as well as further neuronal degeneration9
(for a detailed table of the sequence of pathophysiological
events during SCI, see ref 8). The clariﬁcation of this scenario
has oﬀered various potential therapeutic opportunities to
counteract the spreading of secondary injury.
A large number of treatments (molecular, cellular, and
pharmacological) have been proposed as potential therapeutic
approaches, but few of them could be usefully translated to
humans because of poor eﬃcacy. The most probable cause of
these unsatisfactory results lies in SCI progression itself. As
mentioned above, secondary injury involves diﬀerent times for
degenerative pathways, with the contribution of diﬀerent
cellular components, and a single-target therapy is probably
insuﬃcient to counteract its spread. Now, however, is
increasingly shared the expectation that a combined therapy,
targeting multiple pathological mechanisms at the same time, is
a promising approach.
Many studies have focused on multitherapeutic strategies,
and over half of them show protective eﬀects in preclinical
settings.11 However, combined therapies have to be carefully
planned since diﬀerent drugs may require diﬀerent admin-
istration times to follow the time course of secondary injury and
may not work synergistically, because of the complexity of the
diﬀerent phases. Fine-regulated therapy aimed at multiple
cellular targets remains essential for successful treatment.
Nanoparticles are a promising tool that can be easily adapted
with regards to administration time and biodistribution
(diﬀerent cell targets aﬀected at diﬀerent times after SCI).
The emerging research ﬁeld of nanomedicine oﬀers a variety of
nanodelivery tools to load drugs and gain therapeutic eﬃcacy
by selective time-controlled cell treatment, depending on the
composition and degradation kinetics.12−14
This review oﬀers an overview of the main pathological
events in secondary injury, looking at the pathological role of
CNS cells in each process and the time course of their
contribution after SCI. We will focus on pathological processes
that turn out to be the target of the most promising therapies
proposed in the literature. We assess the most recent single
and multitherapeutic strategies proposed, to highlight the
validity of the multidrug approach, and discuss some critical
aspects. Considering the current limits for the transferability to
the clinic of a multitherapeutic approach, in the ﬁnal part of the
review we will discuss an alternative route of administration
that we believe to be the most promising for the overcoming of
the current therapeutic restrictions. We discuss the advantages
of combining diﬀerent neuroprotective treatments adminis-
tered with nanotools to improve the pharmacokinetics,
biodistribution, and eﬃcacy of free drugs through a cell-
speciﬁc treatment.
■ SECONDARY INJURY: A MULTIFACTORIAL
PROCESS
Secondary injury is due to a complex balance of cellular
responses and contributions to a dynamic SCI microenviron-
ment, which has a profound impact on the global
pathophysiology of the spinal cord. This complex cellular
and extracellular cascade has protective and reparative roles
but also damage exacerbation.15 We can try to simplify it by
deﬁning three steps: (1) Inﬂammation: resident microglia
activate, proliferate, and mediate the recruitment of non-
Figure 1. Schematic representation of secondary injury. (1) Following mechanical damage to the spinal cord (primary injury), resting microglia
became activated and release anti- and pro-inﬂammatory cytokines. (2) Peripheral macrophages are recruited to the injury site and tend to polarize
to the M1 phenotype. (3) Some pro-inﬂammatory cytokines can activate astrocyte, which exacerbate the injury process and create a glial scar. (4)
Impaired neurons are unable to regenerate and under the inﬂuence of the toxic environment undergo apoptosis or necrosis (Adapted with
permission from Zhang, F., Lin, Y.-A., Kannan, S. and Kannan, R. M. Targeting speciﬁc cells in the brain with nanomedicines for CNS therapies. J.
Control. Release Of f. J. Control. Release Soc. 240, 212−226 (2016) Copyright 2016 Elsevier.
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resident immune cells and ﬁbroblasts to the injury site. (2)
Gliosis: astrocyte activation orchestrates the composition of a
glial scar composed of ﬁbroblasts, immune cells, and
extracellular matrix proteins that surround the lesion epicenter,
forming a barrier that prevents axonal regrowth through the
lesion but also helps sequester toxic substances and rescues
penumbral tissues. (3) Axonal degeneration and demyelina-
tion: cells within the scar produce chemorepellants, chemo-
attractants, and trophic factors that inﬂuence the micro-
environment, causing a failure in neuronal regeneration.
Meanwhile, activated immune cells, including endogenous
microglia and peripheral neutrophils and macrophages, adopt a
spectrum of phenotypes with a variety of roles. These include
debris clearance and toxic and trophic factor release that
further inﬂuence the cellular and extracellular microenviron-
ments16 (Figure 1).
The most promising therapeutic strategies can be divided
over three broad targets: (i) inﬂammation and oxidative stress,
for the promotion of a pro-regenerative environment; (ii)
destruction of an inhibitory glial scar with, at the same time,
(iii) enhancement of neuronal regeneration. This classiﬁcation
highlights the important contribution to the progression of the
secondary injury of the pathological processes that underlies
these mechanisms. To recapitulate the main features of these
pathological pathways, we give an updated summary of
preclinical therapeutic options to deﬁne the key cellular
therapeutic targets.
■ INFLAMMATORY RESPONSE TO INJURY
In physiological conditions, the blood−brain barrier (BBB)
limits the entry into the CNS of patrolling bone marrow (BM)-
derived immune cells, while resident microglia provide
physiological surveillance. In response to mechanical primary
injury to the spinal cord, microglia become rapidly activated,
undergoing morphological and molecular changes often
associated with neurotoxicity and initiating the inﬂammatory
cascade that mainly characterizes the acute phase of the
secondary injury. The composition and the potential eﬀects of
the cellular and molecular inﬂammatory cascade change in
relation to the time and distance from the epicenter of the
lesion.
The time course of the inﬂammatory reaction has been
arbitrarily divided into three stages by Shin et al.:18 (1) an early
inﬂammatory stage, from the injury to the ﬁrst 3 days, (2) a
cleaning stage, from approximately 4 days to about 2 weeks
postinjury, and (3) reactive gliosis starting 2 weeks post-
injury.18 This timeline has been deﬁned for rodent models, but
it has been demonstrated by previous studies that, despite
variations in SCI lesions, the main features of neuro-
pathological changes following SCI are similar between rodent
models and human patients.19
The ﬁrst stage involves hemorrhage, destruction of myelin,
cell death, edema, and inﬁltration of inﬂammatory cells due to
the disruption at the BBB. As residents of the spinal cord,
microglia are the ﬁrst cells to respond to tissue damage.20
These cells are important for re-establishing tissue homeo-
stasis.21 They release chemokines and cytokines, both pro-
inﬂammatory (tumor necrosis factor (TNF)-α, interleukin
(IL)-1β, IL-6, interferon (IFN)-γ), and anti-inﬂammatory (IL-
10 and transforming growth factor (TGF)-β1) and other
vasoactive substances, such as reactive oxygen species (ROS),
kinins, histamines, nitric oxide, and elastase, that enhance
recruitment of peripheral leukocytes.22,23 Recruited macro-
phages persist in SCI lesions for as long as any study has
examined, years and months, respectively, for humans and
rodents.24,25
During the cleaning stage, edema is reduced and there is
massive proliferation of macrophages/activated microglia in
the site of the lesion.26,27 In the lesion’s core, macrophages
remove cells and myelin debris, reducing edema and inducing
the formation of a cavity.28
The third phase is characterized by astrogliosis and/or
shrinkage of the spinal cord volume. Astrocytes become the
predominant cell type29 and form a “scarlike” barrier between
the ﬂuid-ﬁlled cavitation and normal tissue.30 We shall discuss
this phase further on. Recently, a later phase of cellular
inﬂammation has been observed, persisting up to 180 days post
injury (DPI), with a peak in the macrophage/microglial
response at 60 DPI, double the site of the earlier peak. This
later peak did not coincide with any change in locomotor
function, suggesting that the second phase is not enough to
aﬀect locomotor recovery.31
The role of neuroinﬂammation is still controversial, being
both beneﬁcial and detrimental for recovery after the trauma.
The immune response may facilitate the recovery from injury
by reducing the size of the lesion, facilitating wound repair, and
stimulating axonal regeneration.32,33 In particular, further
discussion surrounds microglia/macrophage phenotypes, in-
cluding classically activated M1 and alternatively activated M2
macrophages. Although the M1 phenotype is usually associated
with a neurotoxic eﬀect,34 it is also involved in axonal
regeneration,35 while M2 microglia, with neuroprotective
eﬀects, lack an agreeable environment to maintain their
phenotype.36 The current view is that polarization into M1
and M2 microglia phenotypes are the two ends of the same
spectrum. In between, there is a continuum of intermediate
states deﬁned by unique molecular cell signatures.37 Each
cellular substate takes its cue from the changing environment
and responds accordingly by adapting its functional phenotype.
For all these aspects, the inﬂammatory response after injury
could be considered a “double-edged sword”, having both
neuroprotective and neurotoxic properties, and the detrimental
phases of inﬂammation are interspersed with neuroprotective
events.8 This reﬂects the microglial diversity and functional
plasticity, including its immunoregulatory roles after SCI. In
order to exploit this diversity, a thorough understanding of
regulatory mechanisms is required for the best therapeutic
strategy, particularly in regards to neurorepair and neuro-
regeneration. From this perspective, accurate deﬁnition of the
therapeutic window of intervention acquires great importance
for any worthwhile anti-inﬂammatory treatment, because it
should limit the neurotoxic potential and enhance the
reparative mechanisms, depending on the diﬀerent phases of
inﬂammatory reaction during the progression of SCI.
Because the innate immune inﬂammation comes early, the
inﬂammatory reaction oﬀers an attractive option as a ﬁrst
therapeutic target in SCI. Nonsteroidal anti-inﬂammatory
drugs (NSAIDs) have become the focus of various
experimental SCI models as their potent anti-inﬂammatory
eﬀects may be expected to reduce inﬂammation in secondary
damage.38 Experimentally, they display neuro-protective and
apoptotic eﬀects by suppressing axonal regrowth, thus
inhibiting the RhoA pathway, which leads to apoptotic cell
death, in addition to the recovery of motor functions and some
histological improvement. However, histological improvement
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is not always signiﬁcantly associated with any gain of motor
function.7
Rapamycin and minocycline are CNS-penetrating antibiotics
that also inhibit microglial activation and have diﬀerent anti-
inﬂammatory properties.39,40 Minocycline has been examined
in diﬀerent SCI preclinical models,7,41 and the promising
results led to a clinical trial by researchers at the University of
Calgary (ClinicalTrials.gov Identiﬁer: NCT01828203) that
was completed in June 2018. Despite the beneﬁts of this
treatment, its eﬀect was often not restricted only to immune
system cells, and oligodendrocytes, astrocytes, and neurons
could also be aﬀected.42 It therefore appears that systemic
administration of a general immunosuppressant may be
undesirable in a pathological condition such as SCI.43
Finally, Maresin-1, a recently isolated highly conserved
specialized proresolving mediator44 was identiﬁed as an
interventional candidate to attenuate dysregulated inﬂamma-
tion and restore functional recovery after SCI.45
Although all these cited treatments show promising results,
there remain questions about their time window of
applicability and eﬃcacy and their biodistribution in the
injured cord. Further preclinical work is needed to reﬁne and
optimize the treatment paradigms for human study.
■ GLIOSIS
Several days after SCI, astrocytes are activated. This is linked
to resident microglial activation46 and causes synapse
phagocytosis, clearance of debris and dead cells, and the
formation of a glial scar (gliosis), which can restrict the spread
of additional cytotoxic inﬂammation while, at the same time,
limiting the axonal sprouting.47 Astrocytes surrounding the
injury site begin to show hypertrophy with morphological and
molecular changes. They accumulate, extend, and overlap their
processes, forming tight junctions that constitute the scar
around the injury site.48,49 Although the mechanism underlying
the reactive response of astrocytes is not yet fully understood,
it has recently been shown that immune cells play an important
role in the induction and formation of the glial scar.50 After the
lesion, microglia are activated ﬁrst and responsible for the
transformation of the astrocytic phenotype.47 Moreover,
macrophages migrate to the lesion site and produce factors
that induce astrocyte proliferation and their reactive
phenotype.51 In addition, recent evidence show that pericytes,
perivascular cells located on microvessels, react to the lesion
and participate in scar formation.
In particular, following the lesion, a speciﬁc subset of
pericytes (pericitis of type A) begins to proliferate, leaves the
walls of the blood vessels, and diﬀers in cells similar to scarring
ﬁbroblasts that contribute to forming the nucleus of the scar.52
The glial scar has a role in re-establishing the physical and
chemical integrity of the CNS and closing the BBB to reduce
inﬁltration of non-CNS tissue, minimizing infection and the
spread of cellular damage.53,54 On the other hand, the glial scar
produces chemical signals inhibiting axonal sprouting, as
discussed below.
As amply explained in a review by Liddelow and Barres,46
gene proﬁling can be useful to classify the reactive astrocytes
and, most importantly, to deﬁne their function. Similar to the
microglia classiﬁcation, they identiﬁed two astrocyte pheno-
types, A1 and A2. A1 reactive astrocytes turn out to be
responsible for the lack of repair after diﬀerent CNS
pathologies and are considered “harmful”. On the other
hand, A2 astrocytes upregulate many genes that promote
survival and growth of neurons, with a “helpful” function. For
instance, when the formation of A1 astrocytes is inhibited, the
death of axotomized CNS neurons in vivo is prevented.46 On
the other side, the removal of proliferative scar-forming
astrocytes by STAT3-mediated ablation worsens the SCI
outcome, with extensive axon dieback.55 These “helpful”
proliferative astrocytes might well be the A2 phenotype,
becoming important therapeutic mediators.
■ FAILURE IN AXONAL REGENERATION
Axonal regeneration is the therapeutic goal mainly pursued for
post-SCI therapies. Several factors are implicated in the failure
of CNS neurons to regenerate their axons after injury. They
can be divided into two main groups: deﬁcit in intrinsic
regenerative pathways of the axotomized CNS neuron, which
lacks an appropriate cell body response in terms of activating
proper pro-survival gene expression (regenerative associated
genes, RAGs),56 or inhibition by the toxic environment, i.e.,
related to molecules and/or physical barriers that inhibit
axonal growth.57 We are still far from an eﬀective clinical
therapy based on neutralization of inhibitory factors or
enhancement of RAGs.
The extracellular inhibitors regulate axon outgrowth by
acting on receptors located on the growth cones and can be
divided in those associated with myelin (e.g., Nogo, myelin-
associated glycoprotein, oligodendrocyte myelin glycoprotein)
and those related to the glial scar, acting as a chemical (e.g.,
chondroitin sulfate proteoglycans, CSPGs) or physical barrier.
After SCI, CSPGs are upregulated around the injury site,58,59
and this upregulation can inhibit neurite outgrowth in vitro60,61
and in vivo.62 Diﬀerent studies utilized the bacterial enzyme
chondroitinase ABC (ChABC) to digest chondroitin sulfate
glycosaminoglycans (CS-GAGs) of CSPGs. There is robust
preclinical evidence replicated in a number of diﬀerent injury
models of the beneﬁcial eﬀects of ChABC after SCI, such as
enhancement of axon regeneration.63−65
Among RAGs, Growth Associated Protein 43 (GAP-43) is
required for neurite growth since it regulates the actin
cytoskeleton.66 However, increasing the expression of only
one RAG, such as GAP-43, seems not to be suﬃcient to boost
the neuronal regeneration.67,68 Probably the simultaneous
expression of other RAGs is necessary.
Diﬀerent strategies have been proposed to stimulate the
functioning of the regenerative machine or inhibit the
molecules that counteract axonal regeneration. The diﬀerent
approaches can be divided into biologic and pharmacological
treatments.
Biologic Therapy. Among the strategies exploited to
stimulate neuroregeneration after SCI, neurotrophins are
widely used. Neurotrophins are a family of proteins that
regulate synaptic function, neuronal survival, and neuro-
transmitter release and elicit the plasticity and growth of
axons within the adult CNS. The most widely used
neurotrophins are nerve growth factor (NGF), basic ﬁbroblast
growth factor (bFGF), brain-derived neurotrophic factor
(BDNF), and neurotrophin-3 (NT-3).69 Generally, the
majority of studies had signiﬁcant success when neurotrophic
factors are applied in or close to the lesion site during the acute
or subacute phase after SCI. Fewer studies have tested
neurotrophic factors to directly target injured neurons. The
administration route diﬀers among acute injection of
recombinant proteins, subacute or chronic delivery using a
variety of strategies including osmotic minipumps, cell-
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mediated delivery, delivery using polymer release vehicles or
supporting bridges of some sort, or gene therapy to modify
neurons.
Adeno-associated viral (AAV) vectors have been widely
tested to introduce neurotrophic factors into neurons.
Diﬀerent AAV serotypes displayed diﬀerent transduction
eﬃciencies and regional speciﬁcities (AAV5 for neurons in
reticular formation, AAV1 for raphe neurons). Nonviral vectors
are an attractive alternative: they can be targeted to speciﬁc
neuronal subpopulations, oﬀering better safety proﬁles than
viruses and lower production costs. However, nonviral vectors
have lower transfection eﬃciency than viruses, severely limiting
their utility in neuron-targeted delivery applications.70 Though
gene therapy has been successful in treatment of SCI in several
animal models, it is still not available for clinical practice,71 and
other options are required for a selective administration of
neurotrophins.
The neutralization of myelin-mediated inhibition of neurite
outgrowth with anti-Nogo (IN-1) antibodies or other Nogo-
related approaches and the inhibition of Rho activation (e.g.,
with BA-210, Cethrin) are two other biological strategies that
have received considerable attention in the last 2 decades and
are in various stages of clinical translation to promote
endogenous neuroregenerative repair after SCI. Their use in
preclinical models of SCI is amply discussed in a dedicated
review by Kwon and collaborators7 or by Ahuja and Fehlings.41
As the authors explain, it is often diﬃcult to deﬁne the real
beneﬁts of these approaches, mainly because of diﬀerences in
experimental paradigms and some diﬃculty in replicating
positive results. These approaches have already been tested in
clinical trials, but there is some concern in the translation of
these therapies in regards to their biodistribution in the injured
spinal cord. The signaling glycoprotein G-CSF (granulocyte
colony-stimulating factor) can enhance the survival of ischemic
CNS cells, protect against glutamate-induced apoptosis, and
reduce TNF-α and IL-1β expression in vivo.72
Pharmacologic Agents. Among the various neuro-
protective pharmacological treatments reported, we have
selected those with high potential for clinical translation
(because they are already used in other clinical applications).
They are discussed in detail in up-to-date reviews by Ahuja and
collaborators73,41 and Ulndreaj and collaborators74 and
comprise diﬀerent approaches, recapitulated in Table 1.
Another strategy recently pursued is based on microtubule
stabilization. Some compounds such as epothilone D or
paclitaxel, which promote microtubule stabilization, show
neuroprotective properties after systemic injection in contused
rats by activating the intrinsic axonal growth machinery and
reducing the inhibitory ﬁbrotic lesion scar.75,76
■ COMBINATORIAL THERAPIES FOR A SYNERGISTIC
EFFECT
The primary injury sets oﬀ a variety of secondary events, which
result in an expanded lesion area. Ultimately the tissue fails to
regenerate so management of this secondary cascade is an
important ﬁrst step in achieving recovery of normal function.
Single therapies have given only limited eﬀects. This is quite
likely due to a combination of factors responsible for the
staggered development times of diﬀerent biochemical path-
ways of degeneration, which overcome other toxic or
inhibitory factors. To boost the small protective eﬀect seen
after a single neuroprotective treatment, the most promising
strategy is probably simultaneous treatment of diﬀerent
pathological processes. This should give better eﬀects than
single target therapy. In vivo combination studies require great
eﬀort because the introduction of an additional treatment
triples the number of experimental groups.77 However,
diﬀerent studies show that a multitherapy approach is more
eﬀective than single treatments.11 In this direction, recent
research has focused on multitherapeutic compounds to target
the multiple mechanisms involved in the secondary injury.
An extensive literature analysis show that several studies use
combinatorial approach in preclinical models. Most of them
are exposed and summarized in speciﬁc reviews. To oﬀer a
rapid overview on this topic, we can divide the combination
therapies tested in SCI in four groups: (1) combinations of
stem cells transplantation and neurotrophic factors (e.g., NT3,
BDNF); (2) combinations of diﬀerent growth factors (e.g.,
bFGF, NGF) that enhance neuronal survival, act on glial
phenotype, and/or promote plasticity and axonal regrowth;78
(3) combinations of diﬀerent drugs;79 or (4) combinations of
cells/trophic factors and biomaterial scaﬀolds, which could
serve as proper substrates for cell transplantation,80 bridging
the cavity, guiding axonal regeneration, as a cell delivery tool,
and a reservoir for sustained drug delivery. Other studies have
used in addition ChABC to counteract scar formation and
increase axonal growth into the scaﬀold, further improving
behavioral outcome.81
Reviews by Silva and Harvey provide exhaustive summary
tables of, respectively, combinatorial therapies and combina-
torial use of neurotrophic factors for SCI regeneration.11,78 It is
worth mentioning that recent evidence indicates the
importance of motor rehabilitation combined with pharmaco-
logical treatments. In general, an early rehabilitation and a
greater intensity of training seem to be beneﬁcial to favoring
maximum functional recovery. This is demonstrated by
diﬀerent studies on rodent models: pharmacological treatment
combined with rehabilitation lead to re-establishment of gait in
completely transected rats.82 It has also been shown that
Table 1. Neuroprotective Strategies Undergoing Clinical Evaluation for Spinal Cord Injurya
treatment therapeutic action clinical trials
riluzole Blocking tetrodotoxin-sodium channels associated with injured neurons. Inhibition of presynaptic
glutamate release and increased reuptake to modulate excitotoxicity
Phase II/III randomized controlled
trial (NCT01597518)
(Estimated completion date:
December 2018)
magnesium N-methyl-D-aspartate receptor antagonist; antiexcytotoxic and antiapoptotic properties Phase I/II placebo−controlled
(Interrupted)
glibenclamide Blocking nonspeciﬁc cation channels of the capillary endothelium to avoid capillary fragmentation and
hemorrhage
Phase I/II clinical trial
NCT02524379
(Estimated completion date: 2020)
aThese compounds are mainly injected systemically.
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combining treatment with ChABC and rehabilitation promotes
functional recovery in acute spinal cord injury.83 Musieko et al.
showed that combining epidural and pharmacological stim-
ulation to manipulate serotonergic, dopaminergic, and
noradrenergic pathways with rehabilitation restored posterior
limb locomotion in rats.84 Even if also recent clinical trials
demonstrate a beneﬁcial eﬀect of rehabilitation,85 the under-
lying neuronal mechanisms leading to improvements are not
yet fully understood.82
From overall observation and analysis of these combinatorial
studies, we can oﬀer some considerations. The compound
(trophic or growth factors, drugs) is often given systemically,
so its biodistribution is limited by the BScB. Indeed, the BScB
strictly regulate diﬀusion transport of molecules to the spinal
cord parenchyma, allowing only molecules with MW < 400 Da
to cross the endothelium.86 Even if there is a partial rupture of
the BScB following SCI, it is diﬃcult to assess the extent of this
gap and then evaluate how much drug actually manages to
reach the site of injury, meaning higher doses may be needed
to give a protective outcome. Another important critical point
is the lack of selectivity of these treatments after systemic
administration. For example, combined treatments using
diﬀerent growth/trophic factors to promote axonal sprouting
or neuron regeneration may aﬀect diﬀerent axonal populations
in diﬀerent ways and this may result in adverse outcomes such
as enhanced plasticity and/or altered responsiveness of the
nociceptive spinal circuitry.87−89
Finally, when used as single doses, neurotrophic factors gave
limited improvements, due to the impossibility of maintaining
a constant biological eﬀect in vivo. Ideally, the biological eﬀect
should be maintained until the regenerative process ﬁnishes,
requiring multiple doses or invasive therapies.90 These results
suggest that the multitherapeutic approach is promising but it
still needs to be improved.
■ TARGETED DRUG DELIVERY IN SCI
Treatments for SCI can be designed in an increasingly rational
manner, ultimately improving their potential for translation to
the clinic. Although multitherapeutic options provide evident
beneﬁts in SCI preclinical models,11 there is a critical need for
novel methods to treat the injured spinal cord, to improve
biodistribution across the BScB after systemic administration,
to avoid side eﬀects due to the diﬀerent treatments or their
antagonism when administered simultaneously, and most of all
to boost the selectivity of treatments.
A promising solution to improve the multitherapy approach
is targeted therapy, where single compounds are directed
toward their cellular targets, avoiding the interactions with
nontarget cells of systemic distribution. Various approaches
have been proposed to obtain a selective cellular response.
Nanomedicine is the most achievable and an increasingly used
option in the ﬁeld of SCI target therapy. Nanomedicine oﬀers
great potential for improving the eﬃcacy of therapeutic drugs
in clinical settings for many CNS disorders. The uptake of
nanoparticles by target cells and so the interaction with cell
membranes and receptors is strongly associated with the ability
of nanoparticles to form protein corona associating bio-
molecules from the cellular microenvironment and body
ﬂuids.91 Indeed nanoparticles do not interact directly with
the cells, but the protein coronas of nanoparticles play a key
role in the interaction with lipids or protein receptors of the
cell membrane.92 The nanoparticle surface and its speciﬁc
chemical compounds resulting from the engineering processes
(postpolymer functionalization), the methods used for
dispersion, and experimental preparation determine the
selective cell uptake though the activation of speciﬁc signaling
pathways.93
A few studies have proposed new smart nanostructured
biomaterials to deliver therapeutic compounds in situ,
demonstrating that these tools are safe and adjustable for a
multitherapeutic approach.12 Engineered polymeric particles
can oﬀer advantages in many aspects of therapeutic delivery:
while drug entry to the spinal cord is tightly restricted by the
physical limitation of the BScB, drug-carrying nanoparticles
can give signiﬁcantly better CNS pharmacokinetics and
biodistribution than the free drugs.94 Nanoparticles can
improve the solubility of hydrophobic compounds in aqueous
environments, prolong the half-life of therapeutics in the
blood, provide an assortment of controlled release proﬁles,
improve the bioavailability of drugs, and have fewer of the
adverse side eﬀects of delivering therapeutics locally.95−97 A
very important feature of this tool is that the rate of release of
therapeutics from polymeric particles can be tailored by several
methods: particle properties (polymer composition or
porosity), polymer molecular weight and arrangement of the
polymer chains, particle size and shape, as well as the amount
and type of therapeutics loaded.12 The use of nanoparticles for
drug delivery is not only widely reported in preclinical studies
but is now also being implemented for some clinical
applications. Caron and collaborators and Ordikhani and
collaborators provide ample overviews of the use of polymeric
nanoparticles to deliver neurotrophic and growth factors,
drugs, and other therapeutic molecules to treat SCI.12,14
■ NANOMEDICINE TO TARGET DIFFERENT CELLS
SIMULTANEOUSLY
As discussed above, nanomedicine is becoming increasingly
popular in the ﬁeld of SCI thanks to its versatility.
Nanoparticles can be prepared following diﬀerent routes that
depend on the polymeric material and are reviewed in refs 98
and 99. Self-assembly, driven by diﬀerent aﬃnity, of preformed
polymers is the most common method used to synthesize
nanoparticles. Among the diﬀerent strategies used, two of them
are the most widely used: (i) emulsion-solvent evaporation and
(ii) nanoprecipitation or solvent diﬀusion. The emulsion-
solvent evaporation is an emulsiﬁcation, using ultrasounds or
microﬂuidizers, of hydrophobic polymeric solution with an
aqueous phase containing surfactants. The organic phase is
then removed under pressure. The nanoprecipitation process
needs two miscible solvents: the polymer soluble in the ﬁrst
solvent but insoluble in the second one (cosolvent). Nano-
precipitation takes place through a quick desolvation of the
polymer when the solvent is added to the nonsolvent driven by
complex phenomena of diﬀusion, ﬂow, and variation of surface
tension. The key diﬀerence between these two methods is that
in nanoprecipitation the presence of surfactants is not required.
Nanoparticles can also be prepared starting from monomers
using emulsion polymerization; strong attention should be paid
to complete removal of catalysts and initiators.100
Diﬀerent studies show that encapsulation of a drug in a
nanoparticle delivery tool can improve the drug’s pharmaco-
logical eﬃcacy compared to its free administration. For
example, because methylprednisolone is already used to treat
SCI, several groups have attempted to improve its local
delivery with the goal of avoiding side eﬀects and improving its
eﬃcacy. The result showed a better outcome than with
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methylprednisolone alone in vivo with reduction of the lesion
and prolonged drug release (4 and 14 days) giving a better
locomotor score for the methylprednisolone-loaded nano-
particles than for methylprednisolone alone.101,102 To further
support the potential of this approach, our laboratory has
developed and used a nanovector delivery tool (poly-ε-
caprolactone-based nanoparticles, PCL) to selectively treat/
target activated microglia. When administered acutely in SCI
mice, PCL loaded with minocycline, a widely used anti-
inﬂammatory drug, acted eﬃciently on the resident microglial
cells reducing the proinﬂammatory response. We did not get
the same result when minocycline was given alone, supporting
the hypothesis that targeted delivery of the drug improves its
eﬃcacy.20 Linking the advantages of nanoparticles as drug
delivery vehicles with the multitherapy strategy, we suggested
that a combined approach using smart drug delivery systems,
able to provide multiple treatments with diﬀerent release
kinetics, could have synergistic action on treatment eﬃcacy.
The key point of this strategy is to obtain a temporally deﬁned
treatment to selectively inﬂuence cell activation at diﬀerent
stages of the secondary injury. Polymeric nanoparticles
speciﬁcally functionalized that can be internalized by cells
(microglia/macrophages or astrocytes) and then selectively
release diﬀerent active compounds could be used.
The rationale of this approach is to reduce inﬂammation,
counteracting the M1/A1 phenotype in the ﬁrst stage and then
help neuroregeneration, by promoting the M2 and A2 pro-
regenerative phenotypes. An early release of anti-inﬂammatory
factors would be beneﬁcial, as resident microglia are the ﬁrst
cells to activate after injury.103 Factors promoting glial scar
degradation would be more useful if embedded in nano-
particles with long-term release. Neuroregeneration, ﬁnally,
could be achieved using nanoparticles functionalized to be
neuron-selective, loaded speciﬁcally with neurotrophic factors.
The further added value of the combined nanoparticle therapy
is in the possibility of ﬁnely adjusting the release of the
treatments over time, following the course of the secondary
lesion. Understanding how diﬀerent kinds of cells are able to
internalize nanoparticles is essential to improve the selectivity
of nanotools. Microglia and macrophages have an intrinsic
ability to take up foreign bodies through their phagocytic
activity. Clathrin-dependent endocytosis is the principal uptake
mechanism, especially in activated microglia, which is the
principal therapeutic target.104 Diﬀerent synthetic nano-
particles have been used to achieve astrocyte selectivity,
though for now studies are limited to in vitro experi-
ments.105,101 Neuron-speciﬁc uptake is the major challenge
because they are not phagocytic and are surrounded by glial
cells in the CNS. Some authors suggest exploiting the ability of
apolipoprotein E (ApoE) to deliver lipids into neurons and
synthesize nanoparticles with a lipid nature, able to interact
with apoE receptors. A review by Zhang and coauthors
provides a summary of platforms reported in recent studies to
target CNS cell populations.17 Although the choice of
nanoparticles is essential to achieve a higher degree of cellular
selectivity and avoid broader treatment of diﬀerent cell types
with the same nanoparticle, the main problem remains the
transition of the biomaterial into the CNS. The intrathecal
route is usually used to treat diﬀerent spinal cord insults,106 but
local delivery by intraparenchymal infusions has gained
increasing favor for the treatment of neurodegenerative
disorders.107 According to our laboratory’s experience, in situ
drug administration can be done with a glass capillary to
maximize the proportion of treated cells.103,108 This technique
has been used in diﬀerent preclinical paradigms and recently
has been proposed in clinical practice.109 Nanoparticles
administered by intraparenchymal infusion could be combined
with vertebral decompression, already practiced on SCI
patients, avoiding diﬀerent surgical interventions.
■ FINAL REMARKS
SCI causes substantial physical and psychological damage to
patients, including paralysis, neuropathic pain, and bladder
dysfunction. To date, there are no valid therapeutic options.
Clinical interventions such as surgery and methylprednisolone
alleviate inﬂammation and pain and limit further damage but
do not lead to functional recovery and present troublesome
side eﬀects. It is increasingly evident that a promising therapy
should target more than one pathological event, so recent
research has focused on setting up multitherapy, where
diﬀerent combinations of compounds are administered
simultaneously. This approach turned out to be more eﬀective
than single treatments in several studies, but some limitations
emerge, including (i) lack of selectivity, (ii) side eﬀects due to
aberrant interactions among the diﬀerent drugs or to systemic
treatment, and (iii) some diﬃculty in ﬁnding the best
therapeutic window. To overcome these limitations, injectable
nanoparticles can localize and sustain the release of molecular
therapeutics to the lesion site in a minimally invasive manner.
Such therapies will most probably be multimodal, where timed
delivery of various constituents (i.e., drugs, biological
compounds) could be used to modulate cell and tissue
responses at the site of injury during the diﬀerent stages of
recovery.
The ability of nanoparticles to control and the sustain the
release of drugs is widely studied and analyzed in several
papers.99,110 The mechanisms behind drug delivery are three:
(i) diﬀusion, (ii) swelling, and (iii) degradation. In diﬀusion
controlled systems, drug delivery is driven by the gradient of
concentration existing between the inside and the outside of
the device. In swelling controlled ones, the swelling step is the
only release rate-controlling phenomenon. Upon contact with
water, the polymer chains “relax”, with a consequent volume
increase. Obviously, the conditions for drug transport in these
two states (nonswollen versus swollen) are fundamentally
diﬀerent and can be used to accurately control the release rate
of the incorporated drug. In the degradation controlled system,
the delivery of drug is promoted by the degradation of the
polymeric structure that takes place in the body via hydrolysis
and/or enzymatic degradation.
Analyzing the diﬀerent stages of secondary injury, we can
identify three main pathological pathways that call for action:
inﬂammation, gliosis, and neurodegeneration. These processes
start at diﬀerent times after injury and are orchestrated by two
principal cell populations: resident microglia and astrocytes,
while neurons are mainly aﬀected by a hostile environment and
the need for regenerative stimuli. A combined therapy with
diﬀerent nanoparticles that can be selectively internalized by
microglia, astrocytes, or neurons, loaded with speciﬁc drugs/
molecules, could limit the spread of secondary injury. Although
a considerable amount of work is still needed to characterize
the use of nanoparticles in SCI properly before clinical trials
are possible, we believe this is a promising therapeutic option.
The versatility of this tool could allow a single in situ injection
of nanoparticles to avoid systemic routes and to achieve a
selective treatment instead of repeated dosing to cover the
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diﬀerent phases after SCI. In addition, the development of new
nanoparticles capable of overcoming the BScB could further
improve the eﬃciency of treatment, reducing the risks
associated with in situ administration. To conclude, this
approach could possibly be adapted to other CNS diseases
where many factors contribute to the worsening of the clinical
outcome.
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